Neurokinin‑1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report

  • Authors:
    • Miguel Muñoz
    • Juan Carlos Crespo
    • José Pedro Crespo
    • Rafael Coveñas
  • View Affiliations

  • Published online on: May 10, 2019     https://doi.org/10.3892/mco.2019.1857
  • Pages: 50-54
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer (LC) is the leading cause of cancer death and is responsible for more than one‑quarter (27%) of all cancer deaths. Non‑small‑cell LC (NSCLC) is the main histological subtype of LC and is the leading cause of mortalities associated with cancer. This case report focused on a patient showing a history of chronic obstructive pulmonary disease (COPD) with a NSCLC squamous cell carcinoma (single mass with a diameter of 8x7 cm, without metastasis). Due to the COPD, neither a surgical treatment (pneumonectomy) nor chemotherapy was possible. After 15 days following the diagnosis, the patient was treated for 45 days with radiotherapy and the neurokinin‑1 receptor, aprepitant (compassionate use, 1,140 mg/day). Radiotherapy was administered to the right lung and mediastinum, reaching 50.4 Gy and then overprinted to 65 Gy. In each successive control, the tumor volume decreased and, after 6 months of treatment, the chest computed tomography scan showed that the tumor mass had disappeared. No side‑effects were observed during the combination therapy; in contrast, the patient was in very good general health with a weight gain and showing no biochemical analytical alteration. This case report suggests a witness episode to the antitumor effect of aprepitant/radiotherapy against NSCLC. Urgent development is required for clinical trials to test the combination treatment (radiotherapy and aprepitant) as an antitumor therapy for patients with LC.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 68:7–30. 2016. View Article : Google Scholar

2 

Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G and Govindan R: Review of ongoing clinical trials in non-small-cell lung cancer: A status report for 2012 from the clinicaltrials.gov web site. J Thorac Oncol. 8:860–865. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Hodkinson PH, MacKinnon A and Sethi T: Targeting growth factors in lung cancer. Chest. 133:1209–1216. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Muñoz M and Coveñas R: Involvement of substance P and the NK-1 receptor in cancer progression. Peptides. 48:1–9. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Muñoz M, González-Ortega A, Rosso M, Robles-Frías MJ, Carranza A, Salinas-Martín MV and Coveñas R: The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides. 38:318–325. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Muñoz M, Rosso M and Coveñas R: Neurokinin-1 receptor antagonists in lung cancer therapy. Lett Drug Des Discov. 14:1465–1476. 2017. View Article : Google Scholar

7 

Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, et al: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1640–1645. 1998. View Article : Google Scholar : PubMed/NCBI

8 

Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J and Douglas SD: A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One. 6:e241802011. View Article : Google Scholar : PubMed/NCBI

9 

Muñoz M and Coveñas R: Safety of neurokinin-1 receptor antagonists. Expert Opin Drugs Safety. 12:673–685. 2013. View Article : Google Scholar

10 

Muñoz M, Pérez A, Coveñas R, Rosso M and Castro E: Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol. 142:105–112. 2004.PubMed/NCBI

11 

Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C and Piruat JI: The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides. 39:427–432. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Yu H, Boyle TA, Zhou C, Rimm DL and Hirsch FR: PD-L1 Expression in lung cancer. J Thorac Oncol. 11:964–975. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Lee M, McCloskey M and Staples S: Prolonged use of aprepitant in metastatic breast cancer and a reduction in CA153 tumour marker levels. Int J Cancer Clin Res. 3:0712016. View Article : Google Scholar

14 

Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI

15 

Medrano S, Gruenstein E and Dimlich RV: Substance P receptors on human astro-cytoma cells are linked to glycogen breakdown. Neurosci Lett. 167:14–18. 1994. View Article : Google Scholar : PubMed/NCBI

16 

Alfieri AB and Cubeddu LX: Efectos de los antagonistas de los receptores NK1 y de la dexametasona sobre la inflamación neurogénica inducida por ciclofosfamida y por radiación X, en la rata. Archivos Venezolanos de Farmacologia y Terapeutica. 23:61–66. 2004.

17 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al: Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2019
Volume 11 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Muñoz, M., Crespo, J.C., Crespo, J.P., & Coveñas, R. (2019). Neurokinin‑1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. Molecular and Clinical Oncology, 11, 50-54. https://doi.org/10.3892/mco.2019.1857
MLA
Muñoz, M., Crespo, J. C., Crespo, J. P., Coveñas, R."Neurokinin‑1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report". Molecular and Clinical Oncology 11.1 (2019): 50-54.
Chicago
Muñoz, M., Crespo, J. C., Crespo, J. P., Coveñas, R."Neurokinin‑1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report". Molecular and Clinical Oncology 11, no. 1 (2019): 50-54. https://doi.org/10.3892/mco.2019.1857